Inflamación crónica, enfermedad coronaria y cáncer: distintas caras de una misma moneda

Pulmonary Artery Denervation: Valid Alternative for Pulmonary Arterial Hypertension Grade 1?

Pulmonary vessels are densely innervated by sympathetic, parasympathetic, and sensitive fibers.  According to the World Health Organization (WHO) pulmonary arterial hypertension (PAH) grade 1 consists of obliterating pulmonary vascular remodeling accompanied by a diminished generation of vessel dilators.   Its pharmacological treatment has certain limitations and sympathetic pulmonary vascular denervation might be a valid treatment alternative,<a href="https://solaci.org/en/2022/12/14/pulmonary-artery-denervation-valid-alternative-for-pulmonary-arterial-hypertension-grade-1/" title="Read more" >...</a>

¿Qué usar para medir funcionalmente una lesión coronaria en el contexto de estenosis aórtica severa?

Edge-to-Edge Repair Reduces Hospitalization and Mortality Rates in Secondary Mitral Valve Regurgitation?

Severe secondary mitral valve regurgitation is associated to hospitalization and mortality.  The COAPT study has shown the superiority of guideline directed medical therapy at maximal tolerated doses according to guidelines (GDMT) plus edge-to-edge transcatheter repair (TEER) versus GMDT alone. However, at present there is no information on the impact of hospitalizations and their relationship to<a href="https://solaci.org/en/2022/11/22/edge-to-edge-repair-reduces-hospitalization-and-mortality-rates-in-secondary-mitral-valve-regurgitation/" title="Read more" >...</a>

We Should Start Considering Pulmonary Hypertension After TAVR

Pulmonary hypertension is associated with higher mortality after both aortic valve replacement and transcatheter aortic valve replacement (TAVR). This is a dynamic phenomenon, and what happens after TAVR —during the periprocedure— and its impact are yet to be evaluated. Researchers conducted a subanalysis of the Japanese OCEAN TAVI Registry, which included 1872 patients who were divided<a href="https://solaci.org/en/2022/10/25/we-should-start-considering-pulmonary-hypertension-after-tavr/" title="Read more" >...</a>

TRICVALVE en pacientes con Insuficiencia tricuspídea severa: resultados alentadores a 6 meses

Patients with INOCA in the ISCHEMIA Trial

There has been an increase in the diagnosis of patients with proven ischemia who did not present obstructive coronary lesions (defined as the absence of stenosis ≥50%), called ischemia with non-obstructive coronary arteries (INOCA). These patients are at a higher risk for major adverse cardiac events (MACE) compared with the rest of the population. The<a href="https://solaci.org/en/2022/10/18/patients-with-inoca-in-the-ischemia-trial/" title="Read more" >...</a>

A Simple Score for Mortality and Cardiac Failure after Edge-to-Edge with MitraClip

Mitral regurgitation (MR) is the most frequent type of valve heart disease, and the COAPT has shown that edge-to-edge with guideline directed medical treatment (GDMT) at maximal tolerated dose (MTD) is superior to medical treatment alone.  However, we did not have a score to predict patient evolution when treated with this strategy. Researchers analyzed the<a href="https://solaci.org/en/2022/10/14/a-simple-score-for-mortality-and-cardiac-failure-after-edge-to-edge-with-mitraclip/" title="Read more" >...</a>

Resultados del estudio COMPARE a 2 años: Balones cubiertos de Paclitaxel con bajas dosis vs altas dosis

Results of the COMPARE Study After 2 Years: Low Dose vs. High Dose Paclitaxel-Coated Balloons

The development of new devices and techniques has expanded the range of patients who benefit from endovascular treatment of femoropopliteal lesions. Paclitaxel-eluting devices have improved clinical results and treated-vessel patency at follow-up compared with conventional angioplasty. Currently, devices with different doses of paclitaxel are available in the market. The COMPARE (Compare I Pilot Study for<a href="https://solaci.org/en/2022/10/14/results-of-the-compare-study-after-2-years-low-dose-vs-high-dose-paclitaxel-coated-balloons/" title="Read more" >...</a>

La enfermedad vascular periférica se asocia a más eventos en el TAVI

Is Right Ventricle-Pulmonary Artery (RV-PA) Coupling Important in Low Risk TAVR?

TAVR has long been an effective strategy to treat aortic stenosis. However, ventricular damage starts further before symptom onset, also affecting the left ventricle, pulmonary vessels, the right ventricle, the tricuspid valve, and the right atrium.  It increases arterial afterload and uncouples the right ventricle and the pulmonary artery, defined by transthoracic echocardiogram as the relationship<a href="https://solaci.org/en/2022/09/30/is-right-ventricle-pulmonary-artery-rv-pa-coupling-important-in-low-risk-tavr/" title="Read more" >...</a>

TCT 2022 | Pulmonary Artery Denervation in Primary Pulmonary Hypertension

Primary Pulmonary Hypertension is behind multiple hospitalizations and pulmonary transplants. Even though its treatment has been advanced, many patients will not respond well.  The PADN-CFDA randomized 128 patients, 63 received pulmonary denervation (PADN) and 65 went to the control group. Primary end point was 6-minute walk distance test at 6 months.  The populations were similar,<a href="https://solaci.org/en/2022/09/21/tct-2022-pulmonary-artery-denervation-in-primary-pulmonary-hypertension/" title="Read more" >...</a>

Resultados alentadores en la válvula mitral percutánea en los pacientes complejos

Is the Cause of Mitral Regurgitation Relevant for MitraClip?

Mitral regurgitation (MR) is the most common valvulopathy: it is present in (at least) 7.5% of patients >75 years old. This pathology can be classified as primary or degenerative MR (DMR) and secondary or functional MR (FMR).   FMR can be caused by dilatation of the left atrium (most often due to atrial fibrillation), occurring in<a href="https://solaci.org/en/2022/09/16/is-the-cause-of-mitral-regurgitation-relevant-for-mitraclip/" title="Read more" >...</a>

The Best of Main Arena - SOLACI-SOCIME 2022

The Best of the Main Arena at SOLACI-SOCIME 2022: TAVR Complex Anatomy

In the transcatheter aortic valve replacement (TAVR) session we had a presentation by Dr. John P. Vavalle (USA), head of the Structural Heart Disease Program at the University of North Carolina at Chapel Hill.  In his presentation, he showed how far the limits of percutaneous aortic valve implantation can be stretched by briefly showing successful<a href="https://solaci.org/en/2022/08/09/the-best-of-the-main-arena-at-solaci-socime-2022-tavr-complex-anatomy/" title="Read more" >...</a>